Eton Pharmaceuticals price target raised to $33 from $17 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Eton Pharmaceuticals (ETON) to $33 from $17 and keeps a Buy rating on the shares. The firm says the company has been “executing aggressively” toward its stated goal of 10 commercial products by the end of 2025. To date, Eton has six commercial products and five late-stage pipeline candidates, up from five commercial products and three late-stage pipeline candidates in Q2 of 2024, the analyst tells investors in a research note. H.C. Wainwright expects the company to have seven commercial products and four late-stage pipeline candidates by mid-2025. It is bullish on Eton’s growth and expects continued pipeline expansion to drive revenue.